Pietri Olivia, Chicaud Matthieu, Andreani Tony, Chrétien Yves, Limousin Wendy, Lemoinne Sara, Chazouilleres Olivier, Wendum Dominique
AP-HP, Saint-Antoine Hospital, Department of Hepatology, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (CRMR MIVB-H), ERN RARE-LIVER, Sorbonne Université, Paris, France.
AP-HP, Hôpital Saint Antoine, Department of Pathology, Paris, France.
Dig Dis Sci. 2025 Mar;70(3):1178-1189. doi: 10.1007/s10620-024-08730-0. Epub 2024 Dec 16.
BACKGROUND & AIMS: Liver biopsy contribution in patients with unexplained elevation of transaminases is not clearly established. The aim was to study liver biopsy contribution in patients with unexplained elevated transaminases strictly defined according to the current guidelines, reflecting the present clinical practice.
In a retrospective study, we identified all the liver biopsies performed in patients with elevated transaminases for at least six months. Patients with a particular context, or with an identified cause of liver disease were excluded. The biopsies were classified according to the 4 following injury patterns: hepatitic, biliary, steatotic, vascular.
87 patients were included. Liver biopsy showed minimal changes or a normal histology in 48%, a steatotic pattern in 21%, a hepatitic pattern in 13%, a vascular pattern in 8%, a biliary pattern in 1%, and a mixed pattern in 8%. A cause could be determined in 21% of patients with normal histology, 85% with steatosis, 56% with hepatitis, 75% with biliary, but in none with isolated vascular pattern. Liver biopsy had important clinical and therapeutic implications in 15% of patients, with a diagnosis of autoimmune hepatitis, primary biliary cholangitis or metabolic dysfunction-associated steatohepatitis. Elevation of transaminases > 10 upper normal limit was present in all the patients with confirmed autoimmune hepatitis, but in only 7% of others.
Liver biopsy had important clinical and therapeutic implications in 15% of patients. However, the majority of patients had minimal changes without a cause, or minor vascular lesions of uncertain significance.
肝活检在不明原因转氨酶升高患者中的作用尚未明确确立。本研究旨在探讨严格按照现行指南定义的不明原因转氨酶升高患者中肝活检的作用,以反映当前临床实践情况。
在一项回顾性研究中,我们确定了所有转氨酶升高至少6个月的患者所进行的肝活检。排除有特殊情况或已明确肝病病因的患者。根据以下4种损伤模式对活检结果进行分类:肝炎型、胆汁淤积型、脂肪变性型、血管型。
共纳入87例患者。肝活检显示48%的患者有轻微改变或组织学正常,21%为脂肪变性型,13%为肝炎型,8%为血管型,1%为胆汁淤积型,8%为混合型。组织学正常的患者中21%可确定病因,脂肪变性患者中85%可确定病因,肝炎患者中56%可确定病因,胆汁淤积患者中75%可确定病因,但孤立血管型患者均未明确病因。肝活检对15%的患者有重要临床和治疗意义,这些患者被诊断为自身免疫性肝炎、原发性胆汁性胆管炎或代谢功能障碍相关脂肪性肝炎。所有确诊自身免疫性肝炎的患者转氨酶均升高超过正常上限10倍,但其他患者中仅7%如此。
肝活检对15%的患者有重要临床和治疗意义。然而,大多数患者有轻微改变且无病因,或有意义不明确的轻微血管病变。